Q4 2014 13F Holders as of 31 Dec 2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
7,115,554
-
Shares change
-
-70,452
-
Total reported value, excl. options
-
$82,816,339
-
Value change
-
-$6,653,680
-
Number of buys
-
30
-
Number of sells
-
-21
-
Price
-
$11.64
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2014
64 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2014.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7,115,554 shares
of 236,234,693 outstanding shares and own 3% of the company stock.
Largest 10 shareholders include Novo A/S (1,516,387 shares), EAGLE ASSET MANAGEMENT INC (1,222,631 shares), HealthCor Management, L.P. (845,254 shares), FMR LLC (724,200 shares), RA CAPITAL MANAGEMENT, LLC (597,363 shares), BlackRock Fund Advisors (457,284 shares), VANGUARD GROUP INC (231,325 shares), BALYASNY ASSET MANAGEMENT LLC (228,934 shares), MORGAN STANLEY (123,535 shares), and Cormorant Asset Management, LLC (118,000 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.